about
Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South AfricaAdverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection.Hypersensitivity reactions to HIV therapy.The metabolic effects of lopinavir/ritonavir in HIV-negative menArtemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals.Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adultsDrug interactions in the management of HIV infection.Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results.Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.Drug interactions in the management of HIV infection: an update.Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapyBioavailability enhancement of a BCS IV compound via an amorphous combination product containing ritonavir.Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice.Uveitis associated with concurrent administration of rifabutin and lopinavir/ritonavir (Kaletra).Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine.Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir.Simplification and first validation of a short battery of patient questionnaires for clinical management of HIV-infected patients: The HIV-SQUAD (Symptom Quality of life Adherence) Questionnaire.Analysis of possible drug-drug interactions between ritonavir and other antiretrovirals in a section of the private health care sector in South Africa.
P2860
Q33279183-C0A75984-E31C-49D8-8CC9-EFA3EC74EDB3Q34594695-3E92B56A-8059-47FF-884F-86098C3EC621Q34976463-A37EDE3E-6124-473B-93C5-F90651FB000BQ35194394-D495D306-DC98-4C99-B3A9-710136E5A081Q35692270-8FF2F60E-1972-4509-93E0-1B034D36EEA0Q35883504-919F6C78-8AB6-442F-A8FA-D4260D5356ADQ36066083-9F244B1B-4639-4A04-9FB5-B7828B9C889BQ36289127-F74ABF01-B15D-4091-8E1E-5F3399877961Q36727919-CD513EDF-421C-4CA5-A1C3-082F6FB34FAAQ37000733-8EC5D711-5CFB-4DD9-A4B8-7C442B8FC675Q37204276-7F54C738-8144-4FD2-A0A7-A2944A366772Q38954732-624CED6A-59A1-4606-A75A-C704DAA89E2FQ40903070-74AD1799-1337-456D-A2BB-8D49869FB9A3Q46929981-CB3C4530-AF3D-40EB-9074-89730BDB0773Q48006398-FAE7048A-FFDC-404C-A887-03BA6E64E2E2Q48499508-B96AC6D6-CBEB-4B79-B0EA-90BB49F16597Q49051432-4EEF1C05-C799-4D43-9D72-8A3CEC243786Q55208876-C9A15D3A-7C0C-4F1F-B627-D9245465D7A5
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Kaletra (lopinavir/ritonavir).
@ast
Kaletra (lopinavir/ritonavir).
@en
Kaletra
@nl
type
label
Kaletra (lopinavir/ritonavir).
@ast
Kaletra (lopinavir/ritonavir).
@en
Kaletra
@nl
prefLabel
Kaletra (lopinavir/ritonavir).
@ast
Kaletra (lopinavir/ritonavir).
@en
Kaletra
@nl
P2093
P2860
P356
P1476
Kaletra (lopinavir/ritonavir).
@en
P2093
Amanda H Corbett
Angela D M Kashuba
Michael L Lim
P2860
P304
P356
10.1345/APH.1A363
P407
P577
2002-07-01T00:00:00Z